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Ashley E Frakes 
ALS is a fatal neurodegenerative disease that affects motor neurons (MNs) resulting in severe 
muscle atrophy and paralysis.  Despite the fact that about 5,600 people are diagnosed with ALS in the US 
each year, there is no cure.  One of the most striking pathological hallmarks observed in patients and 
rodent models of ALS is neuroinflammation, characterized by activation of microglia, the resident 
immune cells of the central nervous system.  Genetic approaches to globally eliminate single 
inflammatory genes in ALS mouse models have largely failed, highlighting the complexity of this 
inflammatory process.  Nuclear Factor-kappa B (NF-κB) regulates many pro-inflammatory mediators 
found in areas of MN death in ALS, and this pathway is activated in the spinal cords of ALS patients.  
Therefore, the purpose of this study is to determine the role of NF-κB, a master regulator of 
inflammation, in ALS.  By immunoblot and immunohistochemical analyses, we determined NF-kB 
activation increases with disease progression in ALS mice and occurs predominantly in microglia.  To 
determine the role of NF-kB activation in microglial-mediated MN death, we utilized an in vitro co-
culture model in which 61% of MNs die when co-cultured with ALS microglia after 72 hours.  NF-kB 
inhibition in ALS microglia fully rescued MNs from microglial-mediated death in vitro.  Remarkably, 
conditional inhibition of NF-kB in microglia in vivo extends survival in the ALS mice by delaying disease 
progression by 51%, one of the longest extensions reported in this severe model.  NF-kB inhibition in 
microglia leads to marked reduction in prototypic inflammatory markers such as CD68, CD86 and iNOS, 
suggesting that NF-kB regulates microglial conversion to a pro-inflammatory, neurotoxic state in ALS.  
Furthermore, we show that constitutive activation of NF-kB selectively in microglia in wild-type mice 
promoted a similar microglial activation state observed in ALS mice.  Strikingly, microglia isolated from 
these constitutively active NF-kB mice rapidly induced 48% MN death in vitro.  These data provide a 
cellular and molecular mechanism by which microglia induce MN death in ALS and suggest a novel 
therapeutic target to modulate microglial activation and slow the progression of ALS and other 
neurodegenerative diseases by which microglial activation plays a role.    
INTRODUCTION 
 Amyotrophic lateral sclerosis (ALS) is a devastating, fast-progressing neurodegenerative disease 
that causes death of motor neurons in the brainstem, spinal cord, and motor cortex.  Typically within 2-5 
years of clinical onset, patients succumb to the disease due to severe muscle atrophy, paralysis, and 
ultimately denervation of respiratory muscles.  Most ALS cases are classified as sporadic, defined as 
having no familial history of the disease.  The remaining 5-10% of cases are classified as familial and are 
typically inherited in an autosomal dominant fashion.  Despite genetic differences, familial and sporadic 
ALS are clinically indistinguishable.  About 20% of familial cases are associated with mutations in the 
gene superoxide dismutase 1 (SOD1) (Rosen et al., 1993).  Transgenic rodents carrying mutant forms of 
SOD1 develop a similar, progressive motor neuron disease as patients and are used as the gold standard in 
ALS research.  Elegant work utilizing these animals has revealed that non-neuronal cells play a crucial 
role in ALS contributing to motor neuron death via a non-cell autonomous mechanism.  In chimeric mice 
expressing mixtures of mutant SOD1-expressing cells and wild-type cells, wild-type motor neurons 
exhibited signs of ALS pathology when surrounded by mutant SOD1 glia (Clement, 2003).  Similarly, in 
vitro studies have shown that murine astrocytes and microglia expressing mutant SOD1 as well as human 
astrocytes from sporadic and familial ALS patients can induce motor neuron death (Giorgio et al., 2007; 
Haidet-Phillips et al., 2011; Nagai et al., 2007; Xiao et al., 2007). Evidence that multiple cell types 
mediate different aspects of disease emerged from generation of mice expressing a floxed mutant SOD1 
gene.   Removal of the floxed mutant SOD1 gene specifically in motor neurons extended survival by 
delaying disease onset and early disease progression, while excising floxed mutant SOD1 in either 
microglia/macrophages or astrocytes extended survival by slowing disease progression, but not onset 
(Beers et al., 2006; Boillee et al., 2006; Yamanaka et al., 2008).  Similarly, when the myeloid lineage of 
mutant SOD1 mice was replaced with wild-type microglia and macrophages, disease onset was not 
altered, but disease progression was slowed (Beers et al., 2006).  This suggests ALS is a deadly 
convergence of damage developed in multiple cellular compartments that ultimately leads to 
neuromuscular failure.  However, the precise mechanisms by which the individual cell types such as 
astrocytes and microglia contribute to the disease remain unknown.   
 Extensive astrocyte and microglial activation and infiltration of peripheral immune cells at sites 
of motor neuron degeneration is one of the most striking hallmarks of ALS shared by familial and 
sporadic patients as well as rodent models (Hall et al., 1998; Kawamata et al., 1992; Mantovani et al., 
2009).  Mutant SOD1 astrocytes and microglia exhibit increased expression of many pro-inflammatory 
genes including inducible nitric oxide synthase (iNOS), NADPH oxidase (NOX2), TNF- α, prostaglandin 
E2, COX-2 and IL-1β  (Henkel et al., 2006; Hensley et al., 2006; 2003; 2002; Sasaki et al., 2001; Weydt 
and Möller, 2005).  However, genetic approaches to globally eliminate single inflammatory genes in ALS 
mouse models have largely failed to extend survival (Almer et al., 2006; Gowing et al., 2006; Nguyen et 
al., 2001; Son et al., 2001) and in some cases have even hastened disease progression (ref gal3 paper). 
This suggests inflammation in ALS is a combination of compensatory mechanisms acting in a redundant 
manner to induce motor neuron death.  Additionally, inflammation may play opposing roles in different 
cell types and this may change throughout the course of disease.  For these reasons it is necessary to study 
the intricate molecular mechanisms driving the inflammatory response in each cellular compartment and 
to identify up-stream transcription factors that are dysregulated with disease in individual cell types.   
 Nuclear Factor-κB (NF-κB) is known to be a major regulator of inflammation, regulating gene 
expression of pro-inflammatory cytokines, chemokines, enzymes and adhesion molecules, many of which 
are upregulated in ALS. When inflammatory mediators bind their respective receptors, it initiates a 
signaling cascade that leads to phosphorylation and activation of IKKβ (a subunit of the inhibitor of kB 
kinase, IKK, complex).  Activated IKKβ phosphorylates the IkB inhibitory proteins, targeting them for 
ubiquitination and proteosomal degradation, and releases the NF-kB complex (p65-p50) to be 
phosphorylated and translocated to the nucleus to induce gene expression (Ghosh and Karin, 2002).   We 
previously reported NF-κB as the highest-ranked regulator of inflammation by Ingenuity Pathway 
analysis of inflammatory gene array data from astrocytes derived from human post mortem ALS patients 
(Haidet-Phillips et al., 2011). Other laboratories have confirmed by immunohistochemistry that NF-kB is 
activated in glia in familial and sporadic ALS patients (Migheli et al., 1997; Swarup et al., 2011).  
Interestingly, loss of function mutations in the gene optineurin, which is known to negatively regulate 
TNF-α-induced NF-κB activation, have been found in ALS patients (Maruyama et al., 2010).  However, 
it remains unknown whether NF-kB activation in ALS glia is involved in motor neuron death. 
 Since the role of glial-derived inflammation in ALS remains ambiguous, we sought to determine 
how pro-inflammatory signaling regulated by NF-kB in astrocytes and microglia mediates motor neuron 
death in ALS.  In the current study we demonstrate that NF-kB is activated with disease progression in 
the SOD1-G93A mouse model predominately in glia.  Surprisingly, inhibition of NF-kB in astrocytes 
using transgenic and viral-mediated gene delivery approaches did not increase motor function or survival 
in SOD1-G93A mice.  However, crossing the SOD1-G93A mouse model to a NF-kB-GFP reporter strain 
revealed NF-kB activation predominately occurs in microglia.  We developed a robust in vitro co-culture 
model of ALS utilizing adult primary microglia and embryonic stem cell-derived motor neurons. Using 
this in vitro system we show that mutant SOD1 microglia reduce MN survival by 61%.  Notably, 
inhibition of NF-kB in ALS microglia fully rescued motor neurons in the in vitro co-culture model. 
Consistently with these results, inhibition of NF-kB specifically in microglia and macrophages in vivo 
significantly delayed disease progression in the SOD1-G93A mouse model by 51%.  This is one of the 
largest extensions in survival observed in this severe mouse model. Inhibition of NfkB in microglia leads 
to marked reduction in prototypic inflammatory markers such as CD68, CD86 and iNOS, suggesting that 
NF-kB inhibition blocks microglial conversion to a pro-inflammatory, neurotoxic state.  Furthermore, we 
show that constitutive activation of NF-kB selectively in microglia in wild-type mice promoted a similar 
microglial activation state observed in the SOD1-G93A mice.  Strikingly, microglia isolated from these 
animals rapidly induced motor neuron death in vitro.  Taken together, these data provide a cellular and 
molecular mechanism by which microglia induce motor neuron death in ALS and suggest a new 
therapeutic target to modulate microglial activation and slow the progression of ALS and other 
neurodegenerative diseases by which microglial activation plays a role.    
RESULTS 
NF-kB is activated with disease progression in the SOD1-G93A mouse model of ALS 
To investigate the extent of NF-kB activation in the SOD1-G93A model at different stages of disease, we 
analyzed lumbar spinal cord protein for phospho-p65 (active form of NF-kB) from four SOD1-G93A 
mice at 60, 80, 100, and 120 days of age as well as end-stage (typically around 130 days in males and 140 
days in females).  As disease progresses phospho-p65 levels increased two-fold at 120 days of age in 
females and 4.8 fold in males.  At end stage of disease phospho-p65 levels increased 7 fold in females and 
5 fold in males.   
NF-kB activation occurs predominately in microglia in the SOD1-G93A mouse model 
Figure 1. NF-κB is activated with disease 
progression in the SOD1-G93A mouse model of ALS.  
(A) Immunoblot of lumbar spinal cord protein 
isolated from wild-type mice at 120 days of 
age (n=2) and from SOD1-G93A mice at 60, 
80, 100, 120 days of age and at end-stage 
(ES) shows increase in phosphorylation of 
p65 with disease progression (top).  The blot 
was reprobed for p65 (middle) and Actin 
(bottom) as loading controls.  n=4 for each 
time point.   
(B) Fold change of the immunooblot in (A).  
Phospho-p65 was found to be significantly 
upregulated by 2 and 4.8 fold in females and 
males respectively at 120 days and by 7 and 
5 fold at end stage in females and males 
respectively.  Band intensities were 
normalized to p65/Actin. 
	  
To, evaluate the cell types contributing to the 
increase in lumbar NF-κB activation, we crossed the SOD1-
G93A mice to a an NF-κB-GFP reporter mouse strain that 
expresses GFP under the control of NF-κB cis elements 
(Magness et al., 2004).  Since robust NF-κB activation in SOD1-G93A was evident at 120 days in lumbar 
spinal cord protein, we analyzed lumbar spinal cord sections from 120 day old SOD1; NF-κB-GFP mice 
for GFP expression.  We observed a population of bright GFP+ cells identified as microglia by 
overlapping Iba-1 staining (Figure 2A).   We also observed a dim GFP+ population of GFAP+ astrocytes 
(Figure 2B).  We confirmed these findings by analyzing phospho-p65 levels in protein from microglia 
isolated from 120 day old SOD1-G93A mice.   Phospho-p65 was 6.6 fold greater in SOD1-G93A 
microglia than WT microglia (Figure 2D).  To determine the time course of NF-kB activation in 
microglia as disease progresses, we performed immunohistochemistry of SOD1; NF-κB-GFP lumbar 
spinal cord sections prior to disease onset (60 days), at disease onset (100 days), during disease 
progression (120 days), and at end-stage (130 days).  We observed faint GFP signal that co-localized with 
microglial marker, tomato lectin, at 60 days.  There was a marked increase in GFP+ cells beginning at 
Figure 2. NF-kB activation occurs predominately in 
microglia in the SOD1-G93A mouse model 
(A and B) representative high magnification 
images of the cell type positive for NF-
kB-GFP (green) in the lumbar ventral 
horn of an 120 day old SOD1-G93A; 
NF-kB-GFP mouse.  Most 
predominant GFP+ cells (A) also 
positive for microglial marker Iba1+ 
(red).  Other less-striking GFP+ cells 
positive for astrocyte maker GFAP 
(blue). 
 (C)     Representative lumbar ventral horn 
images of WT; NF-kB-GFP at 120 
days, and SOD1-G93A; NF-kB-GFP 
mice at 60, 80, 100, 120, and 130 days 
(end-stage) show increase in NF-kB 
activation (GFP) throughout disease 
progression in SOD1-G93A microglia 
labeled by tomato lectin (red).   
(D)       Immunoblot of protein isolated 
from primary microglia obtained from 120 
day old SOD1-G93A mice and WT 
littermates confirm NF-kB is activated 6.6 
fold in SOD1-G93A microglia compared 
to control littermates.  Microglia from 6 
mice were pooled together for protein 
isolation.  Fold change determined by 
phospho-p65 band intensity normalized 
to p65/Actin. 
 
disease onset progressing up to end-stage that co-stained with tomato lectin suggesting NF-kB activation 
coincides with microgliosis (Figure 2C). This data revealed that microglia, not astrocytes, are the 
prominent cell type contributing to NF-kB activation in disease progression.  
Adult SOD1-G93A microglia induce motor neuron death in an NF-kB dependent mechanism in 
vitro.   
 To determine whether NF-kB activation in microglia is involved in motor neuron death in an in 
vitro co-culture model of ALS, we employed two independent approaches to abolish NF-kB activation in 
microglia. First, we overexpressed DN-ikBα via adenovirus in SOD1-G93A and wild-type microglia.  We 
also employed a genetic approach by isolating microglia from SOD1-G93A; IKKβf/f mice and infecting 
the microglia in vitro with an adenovirus expressing cre recombinase to remove IKKβf/f in microglia post-
isolation.  After 12 hours of co-culture with 
SOD1-G93A microglia, we observed no 
difference in motor neuron survival or axon 
length of the motor neurons compared to 
WT controls (Figure 3A).  However, after 
72 hours of co-culture we observed a 61% 
reduction in motor neuron survival and 
marked reduction in axon length when 
motor neurons were co-cultured with SOD1-
G93A microglia compared to WT (Figure 
3B).  Inhibiting NF-kB, either transgenically 
or by overexpression of DN-ikBα, fully 
rescued motor neuron axon length and 
survival in vitro to wild-type levels (Figure 
Figure 3.  SOD1-G93A microglia induce MN death in an NF-kB-
dependent mechanism 
 (A and B) Representative microscopic fields (A) and entire well 
counts (B) of Hb9-GFP+ motor neurons after 12 hours and 72 hours 
in co-culture with WT or SOD1-G93A microglia not infected (black 
bars) or infected with Ad-RFP (dashed bars) or Ad-DNikBα (white 
bars) show NF-kB inhibition rescues motor neuron survival.  Co-
culturing MNs with either WT;IKKbf/f or SOD1-G93A; IKKβf/f  
microglia infected with Ad-cre (dashed bars) confirmed this result.   
(C and D) Quantification of nitric oxide (C) and TNF-α (D) in the co-
culture medium by ELISA confirms SOD1-G93A inflammation was 
dampened with NF-kB inhibition. 
3A and 3B).  We evaluated the efficiency of NF-kB inhibition by measuring nitric oxide (NO) and TNF-α 
levels in the co-culture medium.  When NF-kB was inhibited, nitric oxide levels decreased 1.75 fold to 
0.5 fold compared to WT (Figure 3C).  TNF-α levels were reduced 2 fold compared to WT (Figure 3D).  
These data suggest that SOD1-G93A microglia induce motor neuron death in an NF-kB dependent 
mechanism. 
Conversely, to evaluate whether constitutively activating NF-kB in WT microglia is sufficient to 
induce motor neuron death in vitro, we isolated microglia from mice containing inducible constitutively 
active IKKβ (IKKβ CA) when cre is expressed.  
Post-isolation we infected microglia from these 
mice with Ad-cre to induce transcription of 
IKKβ CA.   Uninfected microglia from the same 
isolation were used as WT controls.  After 12 
hours in co-culture with WT or IKKβCA 
microglia, we observed no difference in motor 
neuron axon length or survival (Figure 4A).  
Interestingly, after 72 hours in co-culture 
IKKβCA microglia induced a 50% statistical 
decrease in motor neuron survival compared to 
controls (Figure 4B).  These data suggests that 
NF-kB activation in microglia is sufficient to 
induce motor neuron death independent of the 
SOD1-G93A mutation. 
SOD1-G93A microglia induce motor neuron death in an NF-kB dependent mechanism in vivo. 
Figure 4. Wild type microglia induce motor neuron death 
when NF-kB is constitutively active.  (A and B)  
Representative microscopic fields (A) and entire well counts 
(B) of Hb9-GFP+ MNs after 12 and 72 hours in co-culture 
with WT; R26Stopf/f IKKbCA microglia uninfected or infected 
with Ad-cre to induce expression of constitutively active IKKβ 
shows constitutive activation of NF-kB in normal microglia 
induces motor neuron death. 
(C and D) Quantification of nitric oxide (C) and TNF-α (D) in 
the co-culture medium by ELISA  
	  
	  
    Since we have established that (1) NF-kB activation during the disease course in SOD1-G93A 
mice occurs predominantly in microglia (Figure 2) and (2) SOD1-G93A microglia utilize an NF-kB-
dependent mechanism to induce motor neuron death in vitro (Figure 3),  we sought to determine how NF-
kB inhibition in microglia affects the disease course in the SOD1-G93A mouse model.  To accomplish 
this we crossed SOD1-G93A; IKKβf/f mice to mice expressing cre recombinase driven by the promoter 
for the gene c-fms which encodes Colony stimulating factor receptor 1 (CSF-1R).  As shown by 
MacGreen reporter mice that express GFP under the regulation of the c-fms promoter, only microglia 
express CSF-1R in the postnatal mouse brain (Erblich et al., 2011).  To confirm cell-type specificity of 
cre expression driven by the c-fms  (CSF-1R) promoter, we crossed CSF-1R-cre mice to the Rosa26-Td-
Tomato mouse strain that expresses RFP in all cre-expressing cells.  We observed RFP expression only in 
Iba-1+ microglia in the adult mouse spinal cord, and RFP expression was absent in neurons or astrocytes 
(data not shown).   
 Wild-type and SOD1 CSF-1R-cre+ mice homozygous for IKKβf/f displayed serious immune 
dysfunction such as enlarged spleens, eye infections, and missing or very brittle teeth, and therefore could 
not be maintained in the colony long enough to evaluate survival.  Thus, we analyzed mice heterozygous 
for the floxed IKKβ allele (IKKβf/wt).  To determine the efficiency of IKKβ knockdown in heterozygous 
mice, we performed immunohistochemistry for IKKβ in lumbar spinal cord sections from SOD1-G93A; 
IKKβf/wt; CSF-1R-cre+ and cre- mice.   SOD1-G93A; IKKβf/wt; CSF-1R-cre+ showed a decrease in IKKβ 
staining compared to cre negative controls (data not shown).  To ensure knockdown was specific for 
IKKβ, we also evaluated IKKγ levels and observed no difference between cre+ and cre- mice.  To 
confirm that decreasing IKKβ levels would lead to a decrease in NF-kB activation, we analyzed lumbar 
spinal cord protein for phospho-p65 from SOD1-G93A; IKKβf/wt; CSF-1R-cre+ or cre- mice at end-stage. 
Phospho-p65 levels in SOD1-G93A; cre- controls were 8.2 fold greater than WT controls.  Importantly, 
phospho-p65 was reduced 45% in SOD1-G93A; IKKβf/wt; CSF-1R-cre+ mice compared to cre- controls.  
This reduction in NF-kB activation resulted in a 21 day extension in median survival in SOD1-G93A; 
IKKβf/wt; CSF-1R-cre+ mice compared to cre- controls.  While disease onset was not altered (101 days in 
cre- and 100 days in cre+), disease progression was delayed by 19.5 days in cre+ mice which is 51% 
longer than controls (Figure 5A, 5B and 5C).  
 
Conclusions 
In this study we confirm ALS microglia induce motor neuron death in a non-cell autonomous 
mechanism that we determine is through the classical NF-kB signaling pathway.  We show that NF-kB is 
activated with disease progression in the SOD1-G93A mouse model in astrocytes and microglia.  
Interestingly, inhibition of NF-kB in astrocytes using transgenic or viral-mediated gene delivery 
approaches did not improve motor function or survival in SOD1-G93A mice.  However, crossing the 
SOD1-G93A mouse model to a NF-kB-GFP reporter strain revealed NF-kB activation predominately 
occurs in microglia.  Utilizing a robust in vitro co-culture model of ALS containing adult primary 
microglia and embryonic stem cell-derived motor neurons, we show that inhibition of NF-kB in ALS 
microglia fully rescues motor neurons in vitro.  Consistent with these results, inhibition of NF-kB 
specifically in the myeloid lineage in vivo significantly delayed disease progression in the SOD1-G93A 
mouse model by 51%.  These data provide a cellular and molecular mechanism by which microglia 
induce MN death in ALS and suggest a novel therapeutic target to modulate microglial activation and 
Figure 5.  NF-kB inhibition in microglia extends survival in SOD1-G93A mice (A) Kaplan-Meier survival curve 
of SOD1-G93A; IKKbf/wt; CSF1R-cre+ and SOD1-G93A; IKKbf/f; CSF1R-cre- mice confirm NF-kB suppression in 
microglia extends survival by slowing disease progression (C) and not by altering disease onset (B).	  
slow the progression of ALS and other neurodegenerative diseases by which microglial activation plays a 
role.    
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